<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34062930</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>9</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Omics Data and Their Integrative Analysis to Support Stratified Medicine in Neurodegenerative Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4820</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms22094820</ELocationID><Abstract><AbstractText>Molecular and clinical heterogeneity is increasingly recognized as a common characteristic of neurodegenerative diseases (NDs), such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. This heterogeneity makes difficult the development of early diagnosis and effective treatment approaches, as well as the design and testing of new drugs. As such, the stratification of patients into meaningful disease subgroups, with clinical and biological relevance, may improve disease management and the development of effective treatments. To this end, omics technologies-such as genomics, transcriptomics, proteomics and metabolomics-are contributing to offer a more comprehensive view of molecular pathways underlying the development of NDs, helping to differentiate subtypes of patients based on their specific molecular signatures. In this article, we discuss how omics technologies and their integration have provided new insights into the molecular heterogeneity underlying the most prevalent NDs, aiding to define early diagnosis and progression markers as well as therapeutic targets that can translate into stratified treatment approaches, bringing us closer to the goal of personalized medicine in neurology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>La Cognata</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council (CNR), 95126 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morello</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council (CNR), 95126 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavallaro</LastName><ForeName>Sebastiano</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7590-1792</Identifier><AffiliationInfo><Affiliation>Institute for Biomedical Research and Innovation (IRIB), Italian National Research Council (CNR), 95126 Catania, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CTN01_00177_817708</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019295" MajorTopicYN="N">Computational Biology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023281" MajorTopicYN="Y">Genomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="Y">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">multi-omics</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">stratified medicine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>2</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34062930</ArticleId><ArticleId IdType="pmc">PMC8125201</ArticleId><ArticleId IdType="doi">10.3390/ijms22094820</ArticleId><ArticleId IdType="pii">ijms22094820</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kovacs G.G. Molecular pathology of neurodegenerative diseases: Principles and practice. J. Clin. Pathol. 2019;72:725&#x2013;735. doi: 10.1136/jclinpath-2019-205952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jclinpath-2019-205952</ArticleId><ArticleId IdType="pubmed">31395625</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S., Zhang Z., Ang L.C. Clinicopathological overlap of neurodegenerative diseases: A comprehensive review. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 2020;78:30&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">32354648</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W.-J., Cheng X., Fu Y., Zhao M., McGinley J., Westenberger A., Xiong Z.-Q. Rethinking monogenic neurological diseases. BMJ. 2020;371:m3752. doi: 10.1136/bmj.m3752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3752</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkkinen M.G., Kim M.O., Geschwind M.D. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harbor Perspect. Biol. 2018;10:a033118. doi: 10.1101/cshperspect.a033118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a033118</ArticleId><ArticleId IdType="pmc">PMC5880171</ArticleId><ArticleId IdType="pubmed">28716886</ArticleId></ArticleIdList></Reference><Reference><Citation>Santiago J.A., Bottero V., Potashkin J.A. Dissecting the Molecular Mechanisms of Neurodegenerative Diseases through Network Biology. Front. Aging Neurosci. 2017;9:166. doi: 10.3389/fnagi.2017.00166.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00166</ArticleId><ArticleId IdType="pmc">PMC5446999</ArticleId><ArticleId IdType="pubmed">28611656</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrone F., Cacace R., van der Zee J., Van Broeckhoven C. Emerging genetic complexity and rare genetic variants in neurodegenerative brain diseases. Genome Med. 2021;13:59. doi: 10.1186/s13073-021-00878-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-021-00878-y</ArticleId><ArticleId IdType="pmc">PMC8048219</ArticleId><ArticleId IdType="pubmed">33853652</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiaei M. New hopes and challenges for treatment of neurodegenerative disorders: Great opportunities for young neuroscientists. Basic Clin. Neurosci. 2013;4:3&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4202552</ArticleId><ArticleId IdType="pubmed">25337322</ArticleId></ArticleIdList></Reference><Reference><Citation>Yiannopoulou K.G., Anastasiou A.I., Zachariou V., Pelidou S.H. Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research. Biomedicines. 2019;7:97. doi: 10.3390/biomedicines7040097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines7040097</ArticleId><ArticleId IdType="pmc">PMC6966425</ArticleId><ArticleId IdType="pubmed">31835422</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong S., Ling J., Ballantyne A., Lysaght T., Xafis V. Perceptions of &#x2018;Precision&#x2019; and &#x2018;Personalised&#x2019; Medicine in Singapore and Associated Ethical Issues. Asian Bioeth. Rev. 2021;13:179&#x2013;194. doi: 10.1007/s41649-021-00165-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41649-021-00165-3</ArticleId><ArticleId IdType="pmc">PMC8079483</ArticleId><ArticleId IdType="pubmed">33959200</ArticleId></ArticleIdList></Reference><Reference><Citation>Erikainen S., Chan S. Contested futures: Envisioning &#x201c;Personalized,&#x201d; &#x201c;Stratified,&#x201d; and &#x201c;Precision&#x201d; medicine. New Genet. Soc. 2019;38:308&#x2013;330. doi: 10.1080/14636778.2019.1637720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14636778.2019.1637720</ArticleId><ArticleId IdType="pmc">PMC6817325</ArticleId><ArticleId IdType="pubmed">31708685</ArticleId></ArticleIdList></Reference><Reference><Citation>Badhwar A., Haqqani A.S. Biomarker potential of brain-secreted extracellular vesicles in blood in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2020;12:e12001. doi: 10.1002/dad2.12001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/dad2.12001</ArticleId><ArticleId IdType="pmc">PMC7085285</ArticleId><ArticleId IdType="pubmed">32211497</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancesario G.M., Toniolo S., Chiasserini D., Di Santo S.G., Zegeer J., Bernardi G., Musicco M., Caltagirone C., Parnetti L., Parnetti S. The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer&#x2019;s Disease Diagnosis: The Italian Selfie. J. Alzheimer&#x2019;s Dis. 2017;55:1659&#x2013;1666. doi: 10.3233/JAD-160975.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-160975</ArticleId><ArticleId IdType="pubmed">27911328</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzoni C., Kia D.A., Vandrovcova J., Hardy J., Wood N.W., Lewis P.A., Ferrari R. Genome, transcriptome and proteome: The rise of omics data and their integration in biomedical sciences. Brief. Bioinforma. 2018;19:286&#x2013;302. doi: 10.1093/bib/bbw114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbw114</ArticleId><ArticleId IdType="pmc">PMC6018996</ArticleId><ArticleId IdType="pubmed">27881428</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasin Y., Seldin M., Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18:1&#x2013;15. doi: 10.1186/s13059-017-1215-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-017-1215-1</ArticleId><ArticleId IdType="pmc">PMC5418815</ArticleId><ArticleId IdType="pubmed">28476144</ArticleId></ArticleIdList></Reference><Reference><Citation>Zielinski J.M., Luke J.J., Guglietta S., Krieg C. High Throughput Multi-Omics Approaches for Clinical Trial Evaluation and Drug Discovery. Front. Immunol. 2021;12:590742. doi: 10.3389/fimmu.2021.590742.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.590742</ArticleId><ArticleId IdType="pmc">PMC8044891</ArticleId><ArticleId IdType="pubmed">33868223</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivier M., Asmis R., Hawkins G.A., Howard T.D., Cox L.A. The Need for Multi-Omics Biomarker Signatures in Precision Medicine. Int. J. Mol. Sci. 2019;20:4781. doi: 10.3390/ijms20194781.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20194781</ArticleId><ArticleId IdType="pmc">PMC6801754</ArticleId><ArticleId IdType="pubmed">31561483</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A., Sidhu J., Goyal A., Tsao J.W. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2020. Alzheimer Disease.</Citation></Reference><Reference><Citation>Crews L., Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer&#x2019;s disease. Hum. Mol. Genet. 2010;19:R12&#x2013;R20. doi: 10.1093/hmg/ddq160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq160</ArticleId><ArticleId IdType="pmc">PMC2875049</ArticleId><ArticleId IdType="pubmed">20413653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bekris L.M., Yu C.E., Bird T.D., Tsuang D.W. Genetics of Alzheimer disease. J. Geriatr. Psychiatr. Neurol. 2010;23:213&#x2013;227. doi: 10.1177/0891988710383571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988710383571</ArticleId><ArticleId IdType="pmc">PMC3044597</ArticleId><ArticleId IdType="pubmed">21045163</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas G., Charbonnier C., Campion D. From Common to Rare Variants: The Genetic Component of Alzheimer Disease. Hum. Hered. 2016;81:129&#x2013;141. doi: 10.1159/000452256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000452256</ArticleId><ArticleId IdType="pubmed">28002825</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren-Shaul H., Spinrad A., Weiner A., Matcovitch-Natan O., Dvir-Szternfeld R., Ulland T.K., David E., Baruch K., Lara-Astaiso D., Toth B., et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer&#x2019;s Disease. Cell. 2017;169:1276&#x2013;1290. doi: 10.1016/j.cell.2017.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.05.018</ArticleId><ArticleId IdType="pubmed">28602351</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehlbaum-Beurdeley P., Sol O., D&#xe9;sir&#xe9; L., Touchon J., Dantoine T., Vercelletto M., Gabelle A., Jarrige A.-C., Haddad R., Lemari&#xe9; J.C., et al. Validation of AclarusDx&#x2122;, a Blood-Based Transcriptomic Signature for the Diagnosis of Alzheimer&#x2019;s Disease. J. Alzheimer&#x2019;s Dis. 2012;32:169&#x2013;181. doi: 10.3233/JAD-2012-120637.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-120637</ArticleId><ArticleId IdType="pubmed">22785402</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen E.H., La Joie R., Wolf A., Strom A., Wang P., Iaccarino L., Bourakova V., Cobigo Y., Heuer H., Spina S., et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Nat. Med. 2020;26:387&#x2013;397. doi: 10.1038/s41591-020-0762-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0762-2</ArticleId><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Fang J., Bekris L.M., Kim Y.H., Pieper A.A., Leverenz J.B., Cummings J., Cheng F. AlzGPS: A genome-wide positioning systems platform to catalyze multi-omics for Alzheimer&#x2019;s drug discovery. Alzheimer&#x2019;s Res. Ther. 2021;13:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804907</ArticleId><ArticleId IdType="pubmed">33441136</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager P.L., Ma Y., McCabe C., Xu J., Vardarajan B.N., Felsky D., Klein H.-U., White C.C., Peters M.A., Lodgson B., et al. A multi-omic atlas of the human frontal cortex for aging and Alzheimer&#x2019;s disease research. Sci. Data. 2018;5:1&#x2013;13. doi: 10.1038/sdata.2018.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2018.142</ArticleId><ArticleId IdType="pmc">PMC6080491</ArticleId><ArticleId IdType="pubmed">30084846</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark C., Dayon L., Masoodi M., Bowman G.L., Popp J. An integrative multi-omics approach reveals new central nervous system pathway alterations in Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Res. Ther. 2021;13:1&#x2013;9. doi: 10.1186/s13195-021-00814-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-021-00814-7</ArticleId><ArticleId IdType="pmc">PMC8015070</ArticleId><ArticleId IdType="pubmed">33794997</ArticleId></ArticleIdList></Reference><Reference><Citation>Xicota L., Ichou F., Lejeune F.-X., Colsch B., Tenenhaus A., Leroy I., Fontaine G., Lhomme M., Bertin H., Habert M.-O., et al. Multi-omics signature of brain amyloid deposition in asymptomatic individuals at-risk for Alzheimer&#x2019;s disease: The INSIGHT-preAD study. EBioMedicine. 2019;47:518&#x2013;528. doi: 10.1016/j.ebiom.2019.08.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.08.051</ArticleId><ArticleId IdType="pmc">PMC6796577</ArticleId><ArticleId IdType="pubmed">31492558</ArticleId></ArticleIdList></Reference><Reference><Citation>Nativio R., Lan Y., Donahue G., Sidoli S., Berson A., Srinivasan A.R., Shcherbakova O., Amlie-Wolf A., Nie J., Cui X., et al. An integrated multi-omics approach identifies epigenetic alterations associated with Alzheimer&#x2019;s disease. Nat. Genet. 2020;52:1024&#x2013;1035. doi: 10.1038/s41588-020-0696-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-020-0696-0</ArticleId><ArticleId IdType="pmc">PMC8098004</ArticleId><ArticleId IdType="pubmed">32989324</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai B., Wang X., Li Y., Chen P.C., Yu K., Dey K.K., Yarbro J.M., Han X., Lutz B.M., Rao S., et al. Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer&#x2019;s Disease Progression. Neuron. 2020;105:975&#x2013;991. doi: 10.1016/j.neuron.2019.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.12.015</ArticleId><ArticleId IdType="pmc">PMC7318843</ArticleId><ArticleId IdType="pubmed">31926610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C., Jagust W., Trojanowski J.Q., Toga A.W., Beckett L. The Alzheimer&#x2019;s disease neuroimaging initiative. Neuroimaging Clin. N. Am. 2005;15:869. doi: 10.1016/j.nic.2005.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nic.2005.09.008</ArticleId><ArticleId IdType="pmc">PMC2376747</ArticleId><ArticleId IdType="pubmed">16443497</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett D.A., Schneider J.A., Arvanitakis Z., Wilson R.S. Overview and findings from the religious orders study. Curr. Alzheimer Res. 2012;9:628&#x2013;645. doi: 10.2174/156720512801322573.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512801322573</ArticleId><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y., Jun G.R., Zhang X., Chung J., Naj A.C., Chen Y., Bellenguez C., Hamilton-Nelson K., Martin E.R., Kunkle B.W., et al. Analysis of Whole-Exome Sequencing Data for Alzheimer Disease Stratified by APOE Genotype. JAMA Neurol. 2019;76:1099&#x2013;1108. doi: 10.1001/jamaneurol.2019.1456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.1456</ArticleId><ArticleId IdType="pmc">PMC6563544</ArticleId><ArticleId IdType="pubmed">31180460</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan H., Flashner-Abramson E., Vasudevan S., Jubran M.R., Cohen E., Kravchenko-Balasha N. Exploring Alzheimer&#x2019;s Disease Molecular Variability via Calculation of Personalized Transcriptional Signatures. Biomolecules. 2020;10:503. doi: 10.3390/biom10040503.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom10040503</ArticleId><ArticleId IdType="pmc">PMC7226317</ArticleId><ArticleId IdType="pubmed">32225014</ArticleId></ArticleIdList></Reference><Reference><Citation>Milind N., Preuss C., Haber A., Ananda G., Mukherjee S., John C., Shapley S., Logsdon B.A., Crane P.K., Carter G.W. Transcriptomic stratification of late-onset Alzheimer&#x2019;s cases reveals novel genetic modifiers of disease pathology. PLoS Genet. 2020;16:e1008775. doi: 10.1371/journal.pgen.1008775.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1008775</ArticleId><ArticleId IdType="pmc">PMC7295244</ArticleId><ArticleId IdType="pubmed">32492070</ArticleId></ArticleIdList></Reference><Reference><Citation>Neff R.A., Wang M., Vatansever S., Guo L., Ming C., Wang Q., Wang E., Horgusluoglu-Moloch E., Song W.-m., Li A., et al. Molecular subtyping of Alzheimer&#x2019;s disease using RNA sequencing data reveals novel mechanisms and targets. Sci. Adv. 2021;7:eabb5398. doi: 10.1126/sciadv.abb5398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abb5398</ArticleId><ArticleId IdType="pmc">PMC7787497</ArticleId><ArticleId IdType="pubmed">33523961</ArticleId></ArticleIdList></Reference><Reference><Citation>Iqbal K., Flory M., Khatoon S., Soininen H., Pirttila T., Lehtovirta M., Alafuzoff I., Blennow K., Andreasen N., Vanmechelen E., et al. Subgroups of Alzheimer&#x2019;s disease based on cerebrospinal fluid molecular markers. Ann. Neurol. 2005;58:748&#x2013;757. doi: 10.1002/ana.20639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20639</ArticleId><ArticleId IdType="pubmed">16247771</ArticleId></ArticleIdList></Reference><Reference><Citation>Toschi N., Lista S., Baldacci F., Cavedo E., Zetterberg H., Blennow K., Kilimann I., Teipel S.J., Melo Dos Santos A., Epelbaum S., et al. Biomarker-guided clustering of Alzheimer&#x2019;s disease clinical syndromes. Neurobiol. Aging. 2019;83:42&#x2013;53. doi: 10.1016/j.neurobiolaging.2019.08.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2019.08.032</ArticleId><ArticleId IdType="pubmed">31585366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerche S., Schulte C., Wurster I., Machetanz G., Roeben B., Zimmermann M., Deuschle C., Hauser A.K., Bohringer J., Krageloh-Mann I., et al. The Mutation Matters: CSF Profiles of GCase, Sphingolipids, alpha-Synuclein in PDGBA. Move. Disord. Off. J. Move. Disord. Soc. 2021 doi: 10.1002/mds.28472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28472</ArticleId><ArticleId IdType="pubmed">33547828</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasuhn J., Br&#xfc;ggemann N., Hessler N., Berg D., Gasser T., Brockmann K., Olbrich D., Ziegler A., K&#xf6;nig I.R., Klein C., et al. An omics-based strategy using coenzyme Q10 in patients with Parkinson&#x2019;s disease: Concept evaluation in a double-blind randomized placebo-controlled parallel group trial. Neurol. Res. Pract. 2019;1:1&#x2013;7. doi: 10.1186/s42466-019-0033-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42466-019-0033-1</ArticleId><ArticleId IdType="pmc">PMC7650116</ArticleId><ArticleId IdType="pubmed">33324897</ArticleId></ArticleIdList></Reference><Reference><Citation>Carling P.J., Mortiboys H., Green C., Mihaylov S., Sandor C., Schwartzentruber A., Taylor R., Wei W., Hastings C., Wong S., et al. Deep phenotyping of peripheral tissue facilitates mechanistic disease stratification in sporadic Parkinson&#x2019;s disease. Prog. Neurobiol. 2020;187:101772. doi: 10.1016/j.pneurobio.2020.101772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2020.101772</ArticleId><ArticleId IdType="pubmed">32058042</ArticleId></ArticleIdList></Reference><Reference><Citation>Hipp G., Vaillant M., Diederich N.J., Roomp K., Satagopam V.P., Banda P., Sandt E., Mommaerts K., Schmitz S.K., Longhino L., et al. The Luxembourg Parkinson&#x2019;s Study: A Comprehensive Approach for Stratification and Early Diagnosis. Front. Aging Neurosci. 2018;10:326. doi: 10.3389/fnagi.2018.00326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2018.00326</ArticleId><ArticleId IdType="pmc">PMC6216083</ArticleId><ArticleId IdType="pubmed">30420802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kia D.A., Zhang D., Guelfi S., Manzoni C., Hubbard L., Reynolds R.H., Botia J., Ryten M., Ferrari R., Lewis P.A., et al. Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. JAMA Neurol. 2021;78:464&#x2013;472. doi: 10.1001/jamaneurol.2020.5257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.5257</ArticleId><ArticleId IdType="pmc">PMC7851759</ArticleId><ArticleId IdType="pubmed">33523105</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronica E., Baas F., Iyer A., ten Asbroek A.L., Morello G., Cavallaro S. Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex. Neurobiol. Dis. 2015;74:359&#x2013;376. doi: 10.1016/j.nbd.2014.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.12.002</ArticleId><ArticleId IdType="pubmed">25500340</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G., Spampinato A.G., Cavallaro S. Molecular Taxonomy of Sporadic Amyotrophic Lateral Sclerosis Using Disease-Associated Genes. Front. Neurol. 2017;8:152. doi: 10.3389/fneur.2017.00152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00152</ArticleId><ArticleId IdType="pmc">PMC5395696</ArticleId><ArticleId IdType="pubmed">28469596</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam O.H., Rozhkov N.V., Shaw R., Kim D., Hubbard I., Fennessey S., Propp N., Consortium N.A., Fagegaltier D., Harris B.T., et al. Postmortem Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation, Oxidative Stress, and Activated Glia. Cell Rep. 2019;29:1164&#x2013;1177. doi: 10.1016/j.celrep.2019.09.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.09.066</ArticleId><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A., Andersen P.M., Moritz T., Marklund S.L., Antti H. ALS patients with mutations in the SOD1 gene have an unique metabolomic profile in the cerebrospinal fluid compared with ALS patients without mutations. Mol. Genet. Metab. 2012;105:472&#x2013;478. doi: 10.1016/j.ymgme.2011.11.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2011.11.201</ArticleId><ArticleId IdType="pubmed">22264771</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q., Sandhu D., Konrad C., Roychoudhury D., Schwartz B.I., Cheng R.R., Bredvik K., Kawamata H., Calder E.L., Studer L., et al. Identification of a Distinct Metabolomic Subtype of Sporadic ALS Patients. bioRxiv. 2018:416396. doi: 10.1101/416396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/416396</ArticleId></ArticleIdList></Reference><Reference><Citation>Devi G., Scheltens P. Heterogeneity of Alzheimer&#x2019;s disease: Consequence for drug trials? Alzheimer&#x2019;s Res. Ther. 2018;10:122. doi: 10.1186/s13195-018-0455-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0455-y</ArticleId><ArticleId IdType="pmc">PMC6300886</ArticleId><ArticleId IdType="pubmed">30567585</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira D., Wahlund L.O., Westman E. The heterogeneity within Alzheimer&#x2019;s disease. Aging. 2018;10:3058&#x2013;3060. doi: 10.18632/aging.101638.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101638</ArticleId><ArticleId IdType="pmc">PMC6286835</ArticleId><ArticleId IdType="pubmed">30428453</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Caselli R.J. Age stratification corrects bias in estimated hazard of APOE genotype for Alzheimer&#x2019;s disease. Alzheimers Dement. 2018;4:602&#x2013;608. doi: 10.1016/j.trci.2018.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trci.2018.09.006</ArticleId><ArticleId IdType="pmc">PMC6226550</ArticleId><ArticleId IdType="pubmed">30450407</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams T., Borchelt D.R., Chakrabarty P. Therapeutic approaches targeting Apolipoprotein E function in Alzheimer&#x2019;s disease. Mol. Neurodegener. 2020;15:8. doi: 10.1186/s13024-020-0358-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-0358-9</ArticleId><ArticleId IdType="pmc">PMC6995170</ArticleId><ArticleId IdType="pubmed">32005122</ArticleId></ArticleIdList></Reference><Reference><Citation>Marioni R.E., Campbell A., Hagenaars S.P., Nagy R., Amador C., Hayward C., Porteous D.J., Visscher P.M., Deary I.J. Genetic Stratification to Identify Risk Groups for Alzheimer&#x2019;s Disease. J. Alzheimer&#x2019;s Dis. 2017;57:275&#x2013;283. doi: 10.3233/JAD-161070.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-161070</ArticleId><ArticleId IdType="pmc">PMC5345653</ArticleId><ArticleId IdType="pubmed">28222519</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee S., Mez J., Trittschuh E.H., Saykin A.J., Gibbons L.E., Fardo D.W., Wessels M., Bauman J., Moore M., Choi S.E., et al. Genetic data and cognitively defined late-onset Alzheimer&#x2019;s disease subgroups. Mol. Psychiatr. 2018;25:2942&#x2013;2951. doi: 10.1038/s41380-018-0298-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0298-8</ArticleId><ArticleId IdType="pmc">PMC6548676</ArticleId><ArticleId IdType="pubmed">30514930</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitelpunkt A., Galili T., Kozlovski T., Bregman N., Shachar N., Markus-Kalish M., Benjamini Y. Novel Alzheimer&#x2019;s disease subtypes identified using a data and knowledge driven strategy. Sci. Rep. 2020;10:1327. doi: 10.1038/s41598-020-57785-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-57785-2</ArticleId><ArticleId IdType="pmc">PMC6987140</ArticleId><ArticleId IdType="pubmed">31992745</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazarian A., Yashin A.I., Kulminski A.M. Summary-Based Methylome-Wide Association Analyses Suggest Potential Genetically Driven Epigenetic Heterogeneity of Alzheimer&#x2019;s Disease. J. Clin. Med. 2020;9:1489. doi: 10.3390/jcm9051489.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9051489</ArticleId><ArticleId IdType="pmc">PMC7290473</ArticleId><ArticleId IdType="pubmed">32429084</ArticleId></ArticleIdList></Reference><Reference><Citation>Oresic M., Lotjonen J., Soininen H. Systems medicine and the integration of bioinformatic tools for the diagnosis of Alzheimer&#x2019;s disease. Genome Med. 2009;1:83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3016625</ArticleId><ArticleId IdType="pubmed">21092145</ArticleId></ArticleIdList></Reference><Reference><Citation>Bredesen D.E. Metabolic profiling distinguishes three subtypes of Alzheimer&#x2019;s disease. Aging. 2015;7:595&#x2013;600. doi: 10.18632/aging.100801.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.100801</ArticleId><ArticleId IdType="pmc">PMC4586104</ArticleId><ArticleId IdType="pubmed">26343025</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood P.L., Medicherla S., Sheikh N., Terry B., Phillipps A., Kaye J.A., Quinn J.F., Woltjer R.L. Targeted Lipidomics of Fontal Cortex and Plasma Diacylglycerols (DAG) in Mild Cognitive Impairment and Alzheimer&#x2019;s Disease: Validation of DAG Accumulation Early in the Pathophysiology of Alzheimer&#x2019;s Disease. J. Alzheimer&#x2019;s Dis. 2015;48:537&#x2013;546. doi: 10.3233/JAD-150336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-150336</ArticleId><ArticleId IdType="pmc">PMC4713833</ArticleId><ArticleId IdType="pubmed">26402017</ArticleId></ArticleIdList></Reference><Reference><Citation>Czech C., Berndt P., Busch K., Schmitz O., Wiemer J., Most V., Hampel H., Kastler J., Senn H. Metabolite profiling of Alzheimer&#x2019;s disease cerebrospinal fluid. PLoS ONE. 2012;7:e31501. doi: 10.1371/journal.pone.0031501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031501</ArticleId><ArticleId IdType="pmc">PMC3281064</ArticleId><ArticleId IdType="pubmed">22359596</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellec P., Dixon R.A., Li L., Masellis M., Duchesne S., Chertkow H., Black S.E., Sapkota S., McFall G.P., Badhwar A. A multiomics approach to heterogeneity in Alzheimer&#x2019;s disease: Focused review and roadmap. Brain J. Neurol. 2020;143:1315&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241959</ArticleId><ArticleId IdType="pubmed">31891371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Zhou Y., Huang F.-J., Tang H.-D., Xu X.-H., Liu J.-J., Wang Y., Deng Y.-L., Ren R.-J., Xu W., et al. Plasma Metabolite Profiles of Alzheimer&#x2019;s Disease and Mild Cognitive Impairment. J. Proteome Res. 2014;13:2649&#x2013;2658. doi: 10.1021/pr5000895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr5000895</ArticleId><ArticleId IdType="pubmed">24694177</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland J.C., Williams-Gray C.H., Barker R.A. The clinical heterogeneity of Parkinson&#x2019;s disease and its therapeutic implications. Eur. J. Neurosci. 2019;49:328&#x2013;338. doi: 10.1111/ejn.14094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.14094</ArticleId><ArticleId IdType="pubmed">30059179</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherian A., Divya K.P. Genetics of Parkinson&#x2019;s disease. Acta Neurol. Belg. 2020;120:1297&#x2013;1305. doi: 10.1007/s13760-020-01473-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13760-020-01473-5</ArticleId><ArticleId IdType="pubmed">32813147</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cognata V., Morello G., D&#x2019;Agata V., Cavallaro S. Copy number variability in Parkinson&#x2019;s disease: Assembling the puzzle through a systems biology approach. Hum. Genet. 2017;136:13&#x2013;37. doi: 10.1007/s00439-016-1749-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-016-1749-4</ArticleId><ArticleId IdType="pmc">PMC5214768</ArticleId><ArticleId IdType="pubmed">27896429</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger R., Klucken J., Weiss D., T&#xf6;nges L., Kolber P., Unterecker S., Lorrain M., Baas H., M&#xfc;ller T., Riederer P. Classification of advanced stages of Parkinson&#x2019;s disease: Translation into stratified treatments. J. Neural Transm. 2017;124:1015&#x2013;1027. doi: 10.1007/s00702-017-1707-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-017-1707-x</ArticleId><ArticleId IdType="pmc">PMC5514193</ArticleId><ArticleId IdType="pubmed">28342083</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu J., Chaudhuri K.R., Bielza C., de Pedro-Cuesta J., Larra&#xf1;aga P., Martinez-Martin P. Parkinson&#x2019;s Disease Subtypes Identified from Cluster Analysis of Motor and Non-motor Symptoms. Front. Aging Neurosci. 2017;9:301. doi: 10.3389/fnagi.2017.00301.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00301</ArticleId><ArticleId IdType="pmc">PMC5611404</ArticleId><ArticleId IdType="pubmed">28979203</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton M., Ben-Shlomo Y., May M.T., Baig F., Barber T.R., Klein J.C., Swallow D.M.A., Malek N., Grosset K.A., Bajaj N., et al. Developing and validating Parkinson&#x2019;s disease subtypes and their motor and cognitive progression. J. Neurol. Neurosurg. Psychiatr. 2018;89:1279&#x2013;1287. doi: 10.1136/jnnp-2018-318337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318337</ArticleId><ArticleId IdType="pmc">PMC6288789</ArticleId><ArticleId IdType="pubmed">30464029</ArticleId></ArticleIdList></Reference><Reference><Citation>Marras C., Lang A. Parkinson&#x2019;s disease subtypes: Lost in translation? J. Neurol. Neurosurg. Psychiatr. 2012;84:409&#x2013;415. doi: 10.1136/jnnp-2012-303455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303455</ArticleId><ArticleId IdType="pubmed">22952329</ArticleId></ArticleIdList></Reference><Reference><Citation>Fereshtehnejad S.-M., Postuma R.B. Subtypes of Parkinson&#x2019;s Disease: What Do They Tell Us About Disease Progression? Curr. Neurol. Neurosci. Rep. 2017;17:34. doi: 10.1007/s11910-017-0738-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-017-0738-x</ArticleId><ArticleId IdType="pubmed">28324303</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis S.J.G. Heterogeneity of Parkinson&#x2019;s disease in the early clinical stages using a data driven approach. J. Neurol. Neurosurg. Psychiatr. 2005;76:343&#x2013;348. doi: 10.1136/jnnp.2003.033530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2003.033530</ArticleId><ArticleId IdType="pmc">PMC1739569</ArticleId><ArticleId IdType="pubmed">15716523</ArticleId></ArticleIdList></Reference><Reference><Citation>Beeler J.A., Erro R., Vitale C., Amboni M., Picillo M., Moccia M., Longo K., Santangelo G., De Rosa A., Allocca R., et al. The Heterogeneity of Early Parkinson&#x2019;s Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients. PLoS ONE. 2013;8:e70244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3731357</ArticleId><ArticleId IdType="pubmed">23936396</ArticleId></ArticleIdList></Reference><Reference><Citation>De Pablo-Fern&#xe1;ndez E., Lees A.J., Holton J.L., Warner T.T. Prognosis and Neuropathologic Correlation of Clinical Subtypes of Parkinson Disease. JAMA Neurol. 2019;76:470. doi: 10.1001/jamaneurol.2018.4377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.4377</ArticleId><ArticleId IdType="pmc">PMC6459129</ArticleId><ArticleId IdType="pubmed">30640364</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Linstow C.U., Gan-Or Z., Brundin P. Precision medicine in Parkinson&#x2019;s disease patients with LRRK2 and GBA risk variants&#x2014;Let&#x2019;s get even more personal. Transl. Neurodegener. 2020;9:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7565766</ArticleId><ArticleId IdType="pubmed">33066808</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasser T. Usefulness of Genetic Testing in PD and PD Trials: A Balanced Review. J. Parkinson&#x2019;s Dis. 2015;5:209&#x2013;215. doi: 10.3233/JPD-140507.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-140507</ArticleId><ArticleId IdType="pmc">PMC4923738</ArticleId><ArticleId IdType="pubmed">25624421</ArticleId></ArticleIdList></Reference><Reference><Citation>Masellis M., Collinson S., Freeman N., Tampakeras M., Levy J., Tchelet A., Eyal E., Berkovich E., Eliaz R.E., Abler V., et al. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson&#x2019;s disease: A pharmacogenetic study. Brain J. Neurol. 2016;139:2050&#x2013;2062. doi: 10.1093/brain/aww109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww109</ArticleId><ArticleId IdType="pubmed">27190009</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss D., Herrmann S., Wang L., Schulte C., Brockmann K., Plewnia C., Gasser T., Sharma M., Gharabaghi A., Kr&#xfc;ger R. Alpha-synuclein gene variants may predict neurostimulation outcome. Move. Disord. 2016;31:601&#x2013;603. doi: 10.1002/mds.26558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26558</ArticleId><ArticleId IdType="pubmed">26880248</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucci S., Ginevrino M., Trezzi I., Monfrini E., Ricciardi L., Albanese A., Avenali M., Barone P., Bentivoglio A.R., Bonifati V., et al. GBA-Related Parkinson&#x2019;s Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort. Move. Disord. Off. J. Move. Disord. Soc. 2020;35:2106&#x2013;2111. doi: 10.1002/mds.28195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28195</ArticleId><ArticleId IdType="pubmed">32658388</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen A., Zeger S.L. Precision medicine: Discovering clinically relevant and mechanistically anchored disease subgroups at scale. J. Clin. Investig. 2019;129:944&#x2013;945. doi: 10.1172/JCI126120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI126120</ArticleId><ArticleId IdType="pmc">PMC6391083</ArticleId><ArticleId IdType="pubmed">30688662</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Longo D.L., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Logroscino G., Traynor B.J., Collins J., Simeone J.C., Goldstein L.A., White L.A. Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature. Neuroepidemiology. 2013;41:118&#x2013;130. doi: 10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M., Heverin M., Doherty M.A., Davis N., Corr E.M., Vajda A., Pender N., McLaughlin R., Hardiman O. Determining the incidence of familiality in ALS. Neurol. Genet. 2018;4:e239. doi: 10.1212/NXG.0000000000000239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000239</ArticleId><ArticleId IdType="pmc">PMC5961194</ArticleId><ArticleId IdType="pubmed">29845113</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari R., Kuhad A., Kuhad A. Edaravone: A new hope for deadly amyotrophic lateral sclerosis. Drugs Today. 2018;54:349. doi: 10.1358/dot.2018.54.6.2828189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/dot.2018.54.6.2828189</ArticleId><ArticleId IdType="pubmed">29998226</ArticleId></ArticleIdList></Reference><Reference><Citation>Dash R.P., Babu R.J., Srinivas N.R. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics. Clin. Pharmacokineti. 2018;57:1385&#x2013;1398. doi: 10.1007/s40262-018-0655-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-018-0655-4</ArticleId><ArticleId IdType="pubmed">29682695</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2018;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D., Mansfield C., Moussy A., Hermine O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front. Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin. Pharmacother. 2017;18:735&#x2013;738. doi: 10.1080/14656566.2017.1319937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2017.1319937</ArticleId><ArticleId IdType="pubmed">28406335</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Krokidis M.G. Transcriptomics in amyotrophic lateral sclerosis. Front. Biosci. 2018;10:103&#x2013;121. doi: 10.2741/e811.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/e811</ArticleId><ArticleId IdType="pubmed">28930607</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar U.G., Milla V., Cynthia Stafford M.Y., Bjourson A.J., Duddy W., Duguez S.M.-R. A Systematic Review of Suggested Molecular Strata, Biomarkers and Their Tissue Sources in ALS. Front. Neurol. 2019;10:400. doi: 10.3389/fneur.2019.00400.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00400</ArticleId><ArticleId IdType="pmc">PMC6527847</ArticleId><ArticleId IdType="pubmed">31139131</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G., Guarnaccia M., Spampinato A.G., Salomone S., D&#x2019;Agata V., Conforti F.L., Aronica E., Cavallaro S. Integrative multi-omic analysis identifies new drivers and pathways in molecularly distinct subtypes of ALS. Sci. Rep. 2019;9:9968. doi: 10.1038/s41598-019-46355-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-46355-w</ArticleId><ArticleId IdType="pmc">PMC6620285</ArticleId><ArticleId IdType="pubmed">31292500</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cognata V., Gentile G., Aronica E., Cavallaro S. Splicing Players Are Differently Expressed in Sporadic Amyotrophic Lateral Sclerosis Molecular Clusters and Brain Regions. Cells. 2020;9:159. doi: 10.3390/cells9010159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9010159</ArticleId><ArticleId IdType="pmc">PMC7017305</ArticleId><ArticleId IdType="pubmed">31936368</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D., de Assis D.R., Corcia P., Pradat P.-F., Blasco H. Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS. Front. Neurol. 2018;9:1126. doi: 10.3389/fneur.2018.01126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01126</ArticleId><ArticleId IdType="pmc">PMC6305341</ArticleId><ArticleId IdType="pubmed">30619076</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;&#xe4;skel&#xe4;inen O., Solje E., Hall A., Katisko K., Korhonen V., Tiainen M., Kangas A.J., Helisalmi S., Pikkarainen M., Koivisto A., et al. Low Serum High-Density Lipoprotein Cholesterol Levels Associate with the C9orf72 Repeat Expansion in Frontotemporal Lobar Degeneration Patients. J. Alzheimer&#x2019;s Dis. 2019;72:127&#x2013;137. doi: 10.3233/JAD-190132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-190132</ArticleId><ArticleId IdType="pmc">PMC6839456</ArticleId><ArticleId IdType="pubmed">31561355</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillemin G.J., Blasco H., Patin F., Descat A., Gar&#xe7;on G., Corcia P., Gel&#xe9; P., Lenglet T., Bede P., Meininger V., et al. A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression. PLoS ONE. 2018;13:e0198116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5988280</ArticleId><ArticleId IdType="pubmed">29870556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K., Zhang Z., O&#x2019;Reilly &#xc9;.J., Berry J.D., Clish C.B., Deik A., Jeanfavre S., Kato I., Kelly R.S., Kolonel L.N., et al. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. 2019;92:e2089&#x2013;e2100. doi: 10.1212/WNL.0000000000007401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007401</ArticleId><ArticleId IdType="pmc">PMC6512888</ArticleId><ArticleId IdType="pubmed">30926684</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G., Cavallaro S. Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: Implications for personalized therapy. Future Med. Chem. 2015;7:1335&#x2013;1359. doi: 10.4155/fmc.15.60.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fmc.15.60</ArticleId><ArticleId IdType="pubmed">26144267</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G., Conforti F.L., Parenti R., D&#x2019;Agata V., Cavallaro S. Selection of Potential Pharmacological Targets in ALS Based on Whole- Genome Expression Profiling. Curr. Med. Chem. 2015;22:2004&#x2013;2021. doi: 10.2174/0929867322666150408112135.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867322666150408112135</ArticleId><ArticleId IdType="pubmed">25850769</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Amadio S., Fabbrizio P., Morello G., Spampinato A.G., Latagliata E.C., Salvatori I., Proietti D., Ferri A., Madaro L., et al. Histaminergic transmission slows progression of amyotrophic lateral sclerosis. J. Cachexia Sarcopenia Muscle. 2019;10:872&#x2013;893. doi: 10.1002/jcsm.12422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12422</ArticleId><ArticleId IdType="pmc">PMC6711424</ArticleId><ArticleId IdType="pubmed">31020811</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S., Fabbrizio P., Amadio S., Napoli G., Verdile V., Morello G., Iemmolo R., Aronica E., Cavallaro S., Volonte C. Histamine Regulates the Inflammatory Profile of SOD1-G93A Microglia and the Histaminergic System Is Dysregulated in Amyotrophic Lateral Sclerosis. Front. Immunol. 2017;8:1689. doi: 10.3389/fimmu.2017.01689.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01689</ArticleId><ArticleId IdType="pmc">PMC5714870</ArticleId><ArticleId IdType="pubmed">29250069</ArticleId></ArticleIdList></Reference><Reference><Citation>Volonte C., Morello G., Spampinato A.G., Amadio S., Apolloni S., D&#x2019;Agata V., Cavallaro S. Omics-based exploration and functional validation of neurotrophic factors and histamine as therapeutic targets in ALS. Ageing Res. Rev. 2020;62:101121. doi: 10.1016/j.arr.2020.101121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101121</ArticleId><ArticleId IdType="pubmed">32653439</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruffini N., Klingenberg S., Schweiger S., Gerber S. Common Factors in Neurodegeneration: A Meta-Study Revealing Shared Patterns on a Multi-Omics Scale. Cells. 2020;9:2642. doi: 10.3390/cells9122642.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9122642</ArticleId><ArticleId IdType="pmc">PMC7764447</ArticleId><ArticleId IdType="pubmed">33302607</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>